Immufact Uses, Dosage, Side Effects and more
Immufact is under investigation in clinical trial NCT02614833 (IMP321 (Eftilagimod Alpha) as Adjunctive to a Standard Chemotherapy Paclitaxel Metastatic Breast Carcinoma).
| Attribute | Details |
|---|---|
| Trade Name | Immufact |
| Generic | Eftilagimod alfa |
| Eftilagimod alfa Other Names | Eftilagimod alfa, Immufact |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
